Workflow
浙江仙琚制药股份有限公司 关于2024年度募集资金存放与使用情况的专项报告

Fundraising Overview - The company raised a total of RMB 999,999,990 through a non-public offering of 72,992,700 shares at a price of RMB 13.70 per share, with a net amount of RMB 987,357,806.75 after deducting issuance costs [1] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations, detailing the storage, usage, and approval processes for the raised funds [2] - A tripartite supervision agreement was signed with the underwriting institution and banks to clarify the rights and obligations of all parties involved [2] Fund Usage - As of December 31, 2024, the company has one dedicated account for the raised funds, with no idle funds used for temporary working capital [5] - There are no changes in the implementation location or method of the investment projects funded by the raised capital [5] - The company reported no surplus funds remaining from the fundraising activities, and all projects are progressing as planned [5] Financial Performance - The company reported a 100% decrease in notes receivable, a 57.97% increase in prepayments, and a 44.66% increase in other non-current assets compared to the beginning of the year [8] - Short-term borrowings increased by 63.19%, while accounts payable rose by 52.15% [8] - The net cash flow from operating activities decreased by 83.1%, primarily due to reduced cash receipts from sales [9] Shareholder Information - The report includes details on the total number of shareholders and the shareholding structure, although no significant changes were noted in the top shareholders [10]